AbbVie (ABBV) vs Johnson & Johnson (JNJ)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Johnson & Johnson (JNJ) has outperformed AbbVie (ABBV) over the past year, gaining 35.2% versus a gain of 17.8%. Over five years, ABBV leads with a +149.2% price change compared with +59.0% for JNJ. Johnson & Johnson is the larger company by market cap ($628.13 billion vs $490.06 billion), about 1.3 times the size, while AbbVie is growing revenue faster (+8.6% vs +6.0%).
On valuation, AbbVie trades at a lower forward P/E (17.1x vs 21.5x for Johnson & Johnson). AbbVie offers the higher dividend yield (2.46% vs 2.01%). Johnson & Johnson converts more of its revenue into profit, with a net margin of 28.5% versus 6.9%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ABBV | JNJ |
|---|---|---|
| Share price | $277.32 | $260.65 |
| Market cap | $490.06B | $628.13B |
| 1-day change | +1.80% | +1.62% |
| YTD return | +19.23% | +23.93% |
| 1-year return | +17.81% | +35.21% |
| 5-year return | +149.17% | +59.01% |
| P/E ratio (TTM) | 78.34 | 30.20 |
| Forward P/E | 17.06 | 21.54 |
| EPS (TTM) | $3.54 | $8.63 |
| Dividend yield | 2.46% | 2.01% |
| Annual dividend | $6.83 | $5.24 |
| Revenue (latest FY) | $61.16B | $94.19B |
| Revenue growth (YoY) | +8.57% | +6.05% |
| Net income (latest FY) | $4.23B | $26.80B |
| Gross margin | 70.24% | 67.88% |
| Operating margin | 24.65% | — |
| Net margin | 6.91% | 28.46% |
| 52-week high | $277.38 | $281.07 |
| 52-week low | $190.75 | $184.66 |
| Distance from 52-week high | -0.02% | -7.27% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +1.25% | +7.29% |
| Average volume | 4.84M | 7.01M |
| Shares outstanding | 1.77B | 2.41B |
| Employees | 57,000 | 138,200 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- JNJ has outperformed ABBV by 17.4 percentage points over the past year.
- AbbVie trades at a higher earnings multiple (78.3x vs 30.2x trailing P/E).
- Johnson & Johnson is more profitable, keeping 28.5 cents of every revenue dollar as net income versus 6.9 cents for AbbVie.
About AbbVie
ABBV stock →AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 57,000 employees
About Johnson & Johnson
JNJ stock →Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech.
Health Care · Biotechnology: Pharmaceutical Preparations · 138,200 employees
ABBV vs JNJ FAQ
Which is bigger, AbbVie or Johnson & Johnson?
Johnson & Johnson (JNJ) is larger, with a market capitalization of $628.13B compared with $490.06B for AbbVie (ABBV).
Which stock has performed better over the past year, ABBV or JNJ?
JNJ returned +35.21% over the past 12 months, compared with +17.81% for ABBV (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, ABBV or JNJ?
JNJ has the lower trailing P/E at 30.2, versus 78.3 for ABBV. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, AbbVie or Johnson & Johnson?
AbbVie has the higher yield at 2.46%, compared with 2.01% for Johnson & Johnson.
Are AbbVie and Johnson & Johnson in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.